tiprankstipranks
Trending News
More News >
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Canadian Market
Advertisement

Medexus Pharmaceuticals Inc (MDP) Earnings Dates, Call Summary & Reports

Compare
65 Followers

Earnings Data

Report Date
Feb 11, 2026
Before Open (Confirmed)
Period Ending
2026 (Q3)
Consensus EPS Forecast
-0.03
Last Year’s EPS
0.04
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The call highlighted the successful launch and adoption of GRAFAPEX, with significant improvements in reimbursement and manufacturing cost reductions. However, the company faced challenges with declining revenue, adjusted EBITDA, and demand for key products due to competitive pressures.
Company Guidance
During the Medexus Pharmaceuticals Second Fiscal Quarter 2026 earnings call, considerable guidance was provided on the performance and outlook of GRAFAPEX. The company reported that product performance has exceeded prelaunch expectations, with October 2025 marking the strongest month of patient demand since the launch. By the end of September 2025, Medexus had engaged with 83% of U.S. transplant centers, with 29% having already ordered GRAFAPEX and 69% of those reordering. For the six months ending September 30, product-level net revenue from GRAFAPEX was $6.2 million, with the fiscal Q2 2026 revenue totaling $3.1 million. The company anticipates that GRAFAPEX will contribute positively to quarterly operating cash flows by fiscal Q3 2026, with expected underlying patient demand of approximately $3 million to $4 million. Additionally, the NTAP program's reimbursement eligibility is projected to significantly enhance adoption and utilization of GRAFAPEX. Overall, Medexus reported fiscal Q2 2026 net revenue of $24.7 million, a decrease from $26.3 million the previous year, with adjusted EBITDA at $4.4 million. Despite a modest net loss for the quarter, positive operating income was achieved, and the company remains optimistic about future growth opportunities.
Successful Launch of GRAFAPEX
GRAFAPEX exceeded prelaunch expectations with the strongest month of patient demand in October 2025. $6.2 million in net revenue was recognized in the first six months, and it is expected to positively contribute to quarterly operating cash flows by fiscal Q3 2026.
Positive Reimbursement Developments
Starting October 1, 2025, eligible procedures under Medicare using GRAFAPEX are eligible for additional reimbursement through the NTAP program, facilitating adoption.
Gross Margin Improvement
Gross margin for fiscal Q2 2026 was 55.7%, an improvement from 53.7% in the same period last year.
Cost Reduction in IXINITY Manufacturing
IXINITY's manufacturing process improvement initiative resulted in a 30% decrease in product level cost of goods since fiscal Q1 2021.

Medexus Pharmaceuticals Inc (TSE:MDP) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TSE:MDP Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 11, 2026
2026 (Q3)
-0.03 / -
0.042
Nov 12, 2025
2026 (Q2)
-0.03 / -0.01
0
Aug 12, 2025
2026 (Q1)
-0.04 / 0.03
0.112-75.00% (-0.08)
Jun 25, 2025
2025 (Q4)
-0.09 / -0.03
0.044-164.52% (-0.07)
Feb 05, 2025
2025 (Q3)
0.05 / 0.04
-0.028250.00% (+0.07)
Nov 07, 2024
2025 (Q2)
0.03 / 0.00
-0.07
Aug 07, 2024
2025 (Q1)
0.07 / 0.11
0.042166.67% (+0.07)
Jun 25, 2024
2024 (Q4)
-0.02 / 0.04
0.478-90.88% (-0.43)
Feb 07, 2024
2024 (Q3)
0.08 / -0.03
-0.09871.43% (+0.07)
Nov 08, 2023
2024 (Q2)
0.00 / -0.07
-0.19764.29% (+0.13)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

TSE:MDP Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
C$2.70C$2.69-0.37%
Aug 12, 2025
C$2.75C$2.67-2.91%
Jun 25, 2025
C$3.35C$3.15-5.97%
Feb 05, 2025
C$3.79C$3.05-19.53%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Medexus Pharmaceuticals Inc (TSE:MDP) report earnings?
Medexus Pharmaceuticals Inc (TSE:MDP) is schdueled to report earning on Feb 11, 2026, Before Open (Confirmed).
    What is Medexus Pharmaceuticals Inc (TSE:MDP) earnings time?
    Medexus Pharmaceuticals Inc (TSE:MDP) earnings time is at Feb 11, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TSE:MDP EPS forecast?
          TSE:MDP EPS forecast for the fiscal quarter 2026 (Q3) is -0.03.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis